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While most asthma in UK children can be controlled with low-moderate dose inhaled corticosteroids, 
there remains a small group with severe disease and poor control despite maximal treatment whose 
needs are unmet; there are stark differences in their healthcare provision compared to adults. Unlike 
adults, children with severe asthma are not treated at specialist centres, clinical trials of novel 
therapeutics are not tailored for children, and novel biologics are being approved without evidence of 
efficacy. In adults, severe asthma is a commissioned service with only named specialist centres able 
to assess patients and prescribe biologics. A systematic assessment at a dedicated severe asthma 
centre is associated with improved quality of life and asthma control and a reduction in health-care 
utilisation(1). This multidisciplinary assessment helps to identify remediable factors such as poor 
adherence and ensures that appropriate patients are started on costly biologics. In contrast, despite 
international guideline recommendations(2), there is no such service provision or specification for 
children in the UK and most other parts of the world, even though evidence confirms children with severe 
asthma have long-term morbidity, including development of chronic obstructive pulmonary disease 
in adulthood(3). Without specialist services children may be exposed to potential harm associated with 
inappropriate prescription of biologics, or be denied an appropriate therapy, while absence of accurate 
monitoring will result in a missed opportunity to assess the benefit of biologics across the lifespan as 
disease modifying agents(4).   
Children with severe, therapy resistant asthma (STRA) and refractory difficult asthma(5) should be 
considered for biologics(2), but until July 2018, the only biologic licenced for children was the anti-IgE 
monoclonal antibody, omalizumab. However, the restricted prescribing guidelines, including a narrow 
serum IgE range, and the variable clinical response in STRA(6), has left a substantial proportion of 
children with unmet therapeutic needs. The exciting pipeline of biologics could help to address the 
needs of a wider group of children with STRA. However, we have three key concerns; firstly, that the 
appropriate studies are not being carried out in children (e.g. inappropriate end-points such as FEV1 are 
selected); secondly, that drug development is aimed at therapeutic targets from adult models of 
disease; and thirdly, there are very little data to guide choosing the optimal biologic for individual 
patients. 
Mepolizumab (monoclonal antibody to IL-5) dramatically reduces asthma attacks in adults. Although 
adolescents (>12 years) were eligible for the trials, the actual numbers included were tiny (about 30 of 
the total 800 plus participants). However, mepolizumab was licensed for use in children aged 6-17 years 
by the European Medicines Agency (EMA) in August 2018, despite the very limited efficacy data in 
children aged >12 years, and the complete absence of efficacy data in those aged 6-11 years.  This is 
clearly of huge concern and contravenes  European  Paediatric  regulations 
(https://www.ema.europa.eu/en/human-regulatory/overview/paediatric-medicines/paediatric- 
regulation). In contrast, omalizumab was only licenced after efficacy was shown in children aged 6-16 
years(6). Although most children with STRA have steroid resistant airway eosinophilia(7,8) which should 
respond to mepolizumab, the eosinophilia may not be due to Thelper2 cytokines, which have been 
difficult to detect in paediatric STRA, highlighting the need for paediatric studies.(9) Biomarkers for the 
sub-group most likely to respond need to be identified in childhood studies. Furthermore, in the context 
of a maturing immune system, and knowing the regulatory function of eosinophils in immune 
homeostasis(10), their circulatory depletion in children could be deleterious. 
We are concerned that, having achieved approval for a paediatric licence by extrapolation of adult data 
for one biologic, the pharmaceutical industry will adopt the same approach for the many other biologics 
currently being approved for adult severe asthma(11). Worryingly, benralizumab, which targets the 
IL-5 receptor on eosinophils and basophils and results in complete depletion of circulating 
eosinophils(12-14) has been approved by the US Food and Drug Administration for children >12 years 
despite only 4% of all participants in the five Phase 3 studies currently published being aged 12-17 
years(15). We accept trials are ongoing in adolescents and studies in children are challenging. We also 
acknowledge regulatory agencies may have provided paediatric approval to avoid children being denied 
access to novel drugs while evidence is collated. But, surely robust efficacy and safety data are 
mandatory before a paediatric licence is granted for drugs whose potential harmful effects cannot be 
predicted from adult studies. If licences are granted then post-marketing surveillance must be mandated. 
Without steps like these, biologics for children will creep into GINA and other guidelines without any 
evidence base.   
To address the current age-discrimination against children in the UK, we have united as a paediatric 
respiratory community to undertake a clinical trial funded by the National Institute for Health Research 
(NIHR). We will use a unified clinical protocol including at least 8 weeks electronic adherence 
monitoring prior to randomisation. The “Treating severe paediatric asthma; a randomised trial of 
mepolizumab and omalizumab (TREAT) trial” will compare the efficacy of omalizumab and 
mepolizumab in children with STRA. It is a non-inferiority trial over 52 weeks with asthma attacks as 
the primary outcome, also investigating biomarkers for response in children. As with the adult 
PREDICTUMAB trial(16) endorsed by the European Respiratory Society, TREAT is a pragmatic trial to 
determine which biologic is best for which individual child. Importantly, we will aim to demonstrate 
the advantages of specialist paediatric centres and encourage childhood STRA to also be commissioned 
as a specialist service. This framework should also be attractive for the pharmaceutical industry to 
engage with paediatricians to design future trials specifically for children and enable efficient recruitment 
and regulatory approval. The need for pragmatic trials will increase exponentially and we are grateful 
to the NIHR for having the foresight to fund TREAT. UK children with severe asthma cannot continue to 
be treated as second class citizens. 
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